oxidative phosphorylation inhibitor IACS-010759

Drug Overview

Oxidative phosphorylation inhibitor IACS-010759 (also known as an oxidative phosphorylation inhibitor) is an investigational, small-molecule, orally bioavailable inhibitor of Mitochondrial Complex I. It is specifically designed to disrupt the electron transport chain (ETC), the metabolic process that cells use to generate energy in the form of adenosine triphosphate (ATP).

In the clinical landscape of March 2026, IACS-010759 represents a cutting-edge approach to cancer metabolism. While many traditional chemotherapies target DNA replication, this agent targets the “power plant” of the cancer cell. Many types of cancer, particularly those that have become resistant to standard treatments, become “addicted” to Oxidative Phosphorylation (OXPHOS) for survival. Developed at the MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS), this drug is engineered to selectively “starve” these metabolism-dependent cancer cells. By cutting off their primary energy source, IACS-010759 forces the cancer cell into a state of metabolic crisis, ultimately leading to cell death.

• Generic Name: Oxidative Phosphorylation Inhibitor IACS-010759.
• Code Name: IACS-010759.
• Drug Class: Mitochondrial Complex I Inhibitor; OXPHOS Inhibitor.
• Mechanism: Selective inhibition of the NADH: ubiquinone oxidoreductase (Complex I) of the mitochondrial electron transport chain.
• Route of Administration: Oral (Capsule).
• FDA Approval Status: Investigational. As of March 2026, IACS-010759 is not FDA-approved. It is currently being evaluated in Phase 1 and Phase 2 clinical trials for hematologic malignancies and advanced solid tumors.

What Is It and How Does It Work? (Mechanism of Action)

IACS-010759 works by “unplugging” the machinery that cancer cells use to breathe and generate fuel.

1. The Mitochondrial “Power Plant”

Most healthy cells can switch between different ways of making energy (like glycolysis or OXPHOS). However, certain “metabolically inflexible” cancer cells rely almost entirely on the mitochondria to produce ATP.

• Complex I Blockade: IACS-010759 binds to Complex I, the first and largest enzyme in the mitochondrial respiratory chain.
• The “Short Circuit”: By blocking this complex, the drug prevents the flow of electrons. This halts the production of ATP and stops the synthesis of vital building blocks like aspartate, which the cell needs to grow.

2. Induction of Metabolic Crisis

When the energy production stops, the cancer cell experiences several lethal events:

• Energy Depletion: The cell runs out of the ATP needed to maintain its basic functions.
• ROS Production: The “short circuit” in the mitochondria causes a buildup of Reactive Oxygen Species (ROS), which are chemically reactive molecules that damage the cell’s internal structures.
• Apoptosis: The combination of energy starvation and internal damage triggers programmed cell death.

3. Targeting High-Demand Tumors

Research has shown that IACS-010759 is particularly effective against tumors with specific genetic “signatures” that make them unable to compensate for the loss of OXPHOS, such as those with mutations in the LKB1 or KRAS pathways.

Clinical Indications and Research Status (2026)

In the current clinical environment, IACS-010759 is being tested in patients whose cancers have specific metabolic vulnerabilities:

• Acute Myeloid Leukemia (AML): AML cells are often highly dependent on OXPHOS. IACS-010759 is being studied for its ability to kill “leukemia stem cells” that are often resistant to standard induction chemotherapy.
• Advanced Solid Tumors: This includes lung cancer, glioblastoma (brain cancer), and pancreatic cancer. Because the brain is a high-energy environment, researchers are particularly interested in whether this drug can treat aggressive brain tumors.
• Treatment-Resistant Cancers: Since many cancers switch to OXPHOS as a way to “hide” from chemotherapy, IACS-010759 is being evaluated as a way to “re-sensitize” tumors to other drugs.
• LKB1-Mutant Non-Small Cell Lung Cancer (NSCLC): Patients with this specific mutation are known to be especially sensitive to mitochondrial inhibitors.

Dosage and Administration Protocols

As an investigational agent, the dosing of IACS-010759 is strictly controlled by clinical trial protocols to ensure patient safety.

Clinical Efficacy and Research Results (2024–2026)

Recent data from Phase 1/2 trials have highlighted both the potential and the challenges of this metabolic approach:

• Antitumor Activity: Early results in 2025 showed that approximately 30% of patients with specific metabolic “signatures” in their tumors achieved stable disease or partial responses.
• Biomarker Success: Research confirmed that measuring the level of aspartate in the blood can be used as a “biomarker” to see if the drug is successfully starving the tumor.
• Metabolic Adaptation: One of the key findings in early 2026 was that some cancers try to “fight back” by increasing their sugar (glucose) intake. This has led to new trials combining IACS-010759 with drugs that block glucose metabolism.

Safety Profile and Side Effects

Because the mitochondria are present in all cells, IACS-010759 has a narrow “therapeutic window,” meaning the dose must be very precise to kill cancer without harming healthy tissue.

1. Neurotoxicity

The most significant side effect observed in trials.

• Symptoms: Peripheral neuropathy (numbness and tingling), gait disturbances (difficulty walking), and cognitive changes.
• Management: These symptoms are often dose-dependent and may require lowering the dose or stopping the drug.

2. Gastrointestinal (GI) Toxicity

• Symptoms: Nausea, vomiting, and diarrhea.
• Elevated Lactic Acid: Because the drug forces cells to use glycolysis (which produces lactic acid), patients must be monitored for lactic acidosis, a potentially dangerous buildup of acid in the blood.

3. Hematologic Effects

• Anemia and Neutropenia: Low red and white blood cell counts, requiring regular blood monitoring.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, IACS-010759 is being used to study “Metabolic Reprogramming.” Researchers are investigating how “quieting” the mitochondria can help Hematopoietic Stem Cells remain in a dormant state, which protects them from damage during aging. In 2026, there is also focus on “Synthetic Lethality.” Scientists are conducting Phase 1 trials to see if IACS-010759 can be combined with PARP inhibitors to create a “double-hit” on the cancer cell’s energy and DNA repair systems.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Metabolic Baseline: Blood tests for lactate, glucose, and electrolytes are mandatory.
• Neurological Exam: A baseline assessment of nerve function and walking ability.

“Do’s and Don’ts” List:

• DO report any “numbness in your toes” or “difficulty keeping your balance” immediately; these could be signs of early neurotoxicity.
• DO maintain adequate hydration, as this helps your body process the metabolic byproducts of the drug.
• DON’T take any “mitochondrial supplements” (like CoQ10 or certain B-vitamins) without consulting your study doctor, as they may actually “feed” the cancer and stop the drug from working.
• DON’T ignore sudden “muscle cramps” or “abdominal pain,” which could be signs of lactic acid buildup.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. IACS-010759 is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist or metabolic specialist regarding your specific diagnosis and clinical trial eligibility.